StockNews.AI
NNVC
StockNews.AI
204 days

NanoViricides Engages CRO for Phase II Clinical Trial

1. NanoViricides engaged a CRO for Phase II trial of NV-387. 2. NV-387 aims to innovate antiviral treatments significantly.

2m saved
Insight
Article

FAQ

Why Bullish?

Successful clinical trials often lead to increased stock prices. Past examples include companies like Gilead Sciences after announcing positive trial results.

How important is it?

Positive advancement in drug trials can significantly impact NNVC's valuation.

Why Long Term?

Phase II results will influence investor confidence and future growth. Long-term market performance is linked to drug development success.

Related Companies

GILDVRTXINCY
SHELTON, CT / ACCESS Newswire / January 27, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum antiviral drug NV-387 further into the regulatory pipeline. "NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as antibiotics revolutionized the treatment of bacterial diseases," said Anil R.

Related News